1. Introduction {#s0005}
===============

Amyotrophic lateral sclerosis (ALS) is characterized by dysfunction of the upper and lower motor neuron compartments of the human nervous system, with relentless disease progression ([@b0455], [@b0460], [@b0325], [@b0250], [@b0190]). Fundamental to the understanding of ALS pathophysiology is the relationship between upper and lower motor neuron dysfunction. In terms of disease origin, it has been hypothesised that ALS originates at a cortical level, with corticomotoneurons mediating lower motor neuron degeneration through a glutamatergic excitotoxic mechanism ([@b0200], [@b0635]; [@b0325], [@b0400], [@b0405], [@b0190]). In contrast, others have proposed a primacy of lower motor neuron dysfunction with upper motor neuron dysfunction occurring as a secondary phenomenon ([@b0670], [@b0220], [@b0055], [@b0450]). A third school of thought proposed that the upper and lower motor neuron degeneration occurs independently with disease spread evolving in a contiguous and random pattern, conforming to the underlying neuronal anatomy ([@b0455], [@b0460]).

Resolving the relationship between upper and lower motor neuron dysfunction, particularly the site of disease onset, could be important for the understanding of ALS pathogenesis. In turn, such concepts would potentially enable identification of novel therapeutic targets and lead to development of treatment strategies for ALS. This review will critically analyse the physiological processes underlying TMS, incorporating discussion about the pathophysiological and diagnostic utility of threshold tracking TMS in ALS, focussing on the potential of the technique as an outcome biomarker in a clinical trial setting.

1.1. Pathophysiological insights provided by paired-pulse threshold tracking TMS {#s0010}
--------------------------------------------------------------------------------

Paired-pulse TMS techniques are invaluable for assessing cortical excitability in neurological diseases ([@b0645], [@b0470], [@b0715], [@b0625]). With implementation of the paired-pulse TMS paradigm the following TMS biomarkers have emerged; short interval intracortical inhibition (SICI), intracortical facilitation (ICF), short interval intracortical facilitation (SICF) and long interval intracortical inhibition (LICI). It has been reported that the above mentioned TMS biomarkers exhibit utility in the understanding of ALS pathogenesis, diagnosis and clinical research ([@b0645], [@b0470]).

1.2. Physiology of SICI and ICF {#s0015}
-------------------------------

Short interval intracortical inhibition and ICF are generated by delivering a subthreshold conditioning stimulus at pre-determined time interval before a test stimulus ([@b0345], [@b0425], [@b0290], [@b0600]). In the original technique, the strength of the conditioning and test stimuli were kept constant and changes in the motor evoked potential (MEP) amplitude were measured ([@b0345], [@b0720], [@b0425]). With interstimulus interval (ISI) set between 1 and 5 ms, the test MEP response is inhibited, a phenomenon referred to as *SICI*. Increasing the ISI to between 7 and 30 ms increases the test MEP amplitude, termed ICF ([@b0105]).

A potential limitation of the "constant stimulus" technique pertains to marked variability in MEP amplitudes with consecutive stimuli ([@b0330], [@b0290]). In order to overcome this limitation, a *threshold tracking technique* was developed, whereby an MEP response of fixed amplitude (0.2 mV ± 20%) is tracked by a test stimulus ([Fig. 1](#f0005){ref-type="fig"}A, B) ([@b0225], [@b0600]). Consequently, SICI is reflected by an increase in test stimulus current required to produce and maintain the fixed MEP target when compared to the unconditioned stimulus, while ICF is represented by the converse \[[Fig. 1](#f0005){ref-type="fig"}D\]. Utility of the threshold tracking technique has been well established in healthy subjects and human disease ([@b0645], [@b0625]). Moreover, a recent study has reported a greater reliability of the threshold tracking technique when compared to the constant stimulus method ([@b0480]).Fig. 1(A) The tracking target of 0.2 mV ( ± 20%) lies in the steepest portion of the stimulus response curve (green color), such that a large variation in motor evoked potential (MEP) amplitude translates to a small variation in transcranial magnetic stimulation (TMS) intensity. (B) When the MEP amplitude is larger than the tracking target (a) the TMS intensity is reduced on subsequent stimulus, while when MEP is smaller (b) the TMS intensity is increased. (C) SICI is mediated by inhibitory GABAergic interneurons located within the primary motor cortex, mostly layers 2 and 3, projecting onto pyramidal cells. (D) Short interval intracortical inhibition (SICI) is reflected by conditioned-test stimulus intensity being greater than zero, while the converse is true for intracortical facilitation (ICF). In amyotrophic lateral sclerosis (ALS) there is a significant reduction in SICI and an increase in ICF, indicative of cortical hyperexcitability. (E) Treatment with the anti-glutamatergic agent riluzole partially normalizes SICI in ALS patients.

Although the precise physiological processes underlying SICI and ICF remain to be fully elucidated, it is now widely accepted that these TMS parameters reflect a balance between inhibitory and facilitatory cortical circuits projecting onto the pyramidal output tracts ([@b0185], [@b0430], [@b0475]). Recordings of descending corticospinal volleys by high cervical epidural electrodes have provided evidence for a cortical basis of both SICI and ICF ([@b0425], [@b0175]). The development of SICI was associated with a reduction in frequency and amplitude of later indirect (I3) waves, but not earlier I1 waves, suggesting that SICI is mediated by activation of intracortical circuits rather than direct excitability of pyramidal neurons ([@b0290]). Neuropharmacological studies have suggested that SICI is predominantly mediated by the activity of GABAergic interneuronal circuits acting via GABA~A~ receptors \[[Fig. 1](#f0005){ref-type="fig"}C\] ([@b0710]). In addition, dopamine agonists increase while dopamine antagonists and noradrenergic agonists reduced SICI ([@b0705], [@b0725], [@b0300], [@b0340]). Recently, cortical modelling studies have indicated that interneuronal circuits located in layers 2 and 3 of the motor cortex were important for SICI generation ([@b0475]).

Two phases of SICI have been identified using the threshold tracking technique, a smaller phase at ISI ≤ 1 ms and larger peak at ISI "2.5--3 ms" \[[Fig. 1](#f0005){ref-type="fig"}C\] ([@b0225], [@b0600], [@b0590], [@b0585]). Synaptic processes acting via GABAergic neuronal circuits (GABA~A~ receptor mediated) were postulated to mediate the second phase of SICI ([@b0710], [@b0160], [@b0305], [@b0170]). The precise mechanisms underlying the first phase of SICI remains uncertain. Relative refractoriness of cortico-cortical axons ([@b0095], [@b0225], [@b0280]), as well as synaptic processes distinct to those that mediating the later phases of SICI ([@b0465], [@b0590]), have been proposed.

Intracortical facilitation is measured using an identical conditioning-test stimulus paradigm as SICI, although the interstimulus intervals range from 8 to 30 ms ([@b0345], [@b0600]). While the physiological process underlying ICF remain to be fully clarified, ICF appears to reflect the activity of excitatory motor cortical circuits that are physiologically distinct from those mediating SICI ([@b0720]). This notion is supported by a higher threshold for activation and the dependence of ICF on the direction of current flow in the motor cortex ([@b0720]). In contrast, others have suggested that the tail end of SICI contributes to net facilitation of ICF ([@b0290]). At a neuropharmacological level, ICF is reduced by GABA agonists and glutamatergic antagonists, while noradrenergic agonists increase ICF ([@b0315], [@b0710], [@b0490], [@b0060], [@b0435], [@b0440], [@b0715]).

1.3. Physiology of SICF {#s0020}
-----------------------

Short interval intracortical facilitation is generated by a conditioning stimulus set to near or above threshold, preceding a test stimulus set to threshold intensity ([@b0535], [@b0720]). The SICF develops over ISIs of 1--5 ms with three distinct peaks reported at 1--1.5 ms, 2.4--2.9 and greater than 4.5 ms ([@b0535], [@b0720], [@b0110]). The threshold tracking TMS technique was recently adapted to generate SICF, revealing two distinct peaks at ISIs of 1.5 and 3 ms ([@b0580]). A cortical origin for SICF has been proposed, with a facilitatory interaction of I-waves produced by conditioning and test stimuli postulated as a likely mechanism ([@b0730], [@b0180]). Separately, disinhibition of inhibitory neuronal circuits has also been suggested as a potential physiological mechanism ([@b0650], [@b0715]). A recent study argued against the latter possibility and suggested that the discordant conclusions may relate to differences in sample size, methodologies or variations in the anatomical arrangements of interneuronal circuits underlying SICF and SICI ([@b0580]).

1.4. Physiology of LICI {#s0025}
-----------------------

Long interval intracortical inhibition is generated by delivering a suprathreshold conditioning stimulus 50--200 ms before a test stimulus ([@b0570], [@b0425]). The magnitude of LICI correlates with the strength of the conditioning stimulus ([@b0570]). LICI can also be assessed by using the threshold tracking technique: LICI then develops over ISIs 50--300 ms and peaks at 150 ms ([@b0600]).

Neuropharmacological studies have suggested that LICI is mediated by long latency inhibitory post synaptic potentials acting via GABA~B~ receptors ([@b0655]). Although LICI and SICI appear to me mediated by distinct cell populations, LICI exerts a suppressive effect on SICI through presynaptic GABA~B~ receptors ([@b0485]).

1.5. Cortical inhibition and facilitation in ALS {#s0030}
------------------------------------------------

In sporadic ALS patients, a reduction or absence of SICI and an increase in ICF \[[Fig. 1](#f0005){ref-type="fig"}C\] have been reported, all indicative cortical hyperexcitability ([@b0285], [@b0680], [@b0735], [@b0515], [@b0520], [@b0690], [@b0600], [@b0635], [@b0050]). The reduction of SICI has been reported as an early and specific feature of ALS, correlating with biomarkers of lower motor neuron dysfunction ([@b0600]), and preceding the onset of detectable LMN dysfunction in sporadic ALS cohorts ([@b0405]). Furthermore, reduction of SICI was associated with specific clinical features of ALS such as the split hand and split hand-plus signs ([@b0030], [@b0400]), as well as contributing to the pattern of disease spread ([@b0385]). Importantly, the reduction of SICI was reported to be an adverse prognostic factor in ALS ([@b0495]), suggesting a potential role for SICI as a prognostic biomarker in ALS.

Separately, SICI is partially normalized by riluzole ([@b0630]), an anti-glutamatergic agent exhibiting modest clinical effectiveness in ALS \[[Fig. 1](#f0005){ref-type="fig"}E\] ([@b0035], [@b0360]). This modulating effect lasts approximately 3 months ([@b0240]), paralleling the clinical efficacy of the drug, and may be related to overexpression of efflux pumps at the blood brain barrier during the disease course ([@b0350]). Irrespective of the underlying mechanisms, riluzole studies have suggested a utility of threshold tracking TMS in assessing biological effectiveness of compounds at an early stage of drug development so as to avoid unnecessary and costly Phase 3 trials.

In addition to the pathophysiological insights provided in classical ALS, threshold tracking TMS has established the presence of cortical hyperexcitability in atypical ALS phenotypes. Specifically, reduced SICI and increased ICF have been documented in the flail arm and leg variants of ALS, as well as primary lateral sclerosis ([@b0610], [@b0260], [@b0395]). Importantly, cortical hyperexcitability correlated with neurodegeneration, underscoring its importance in the pathogenesis of atypical ALS phenotypes.

Features of cortical hyperexcitability have also been reported in familial ALS cohorts, including phenotypes linked to mutations in the superoxide dismutase-1 ([@b0635]), fused in sarcoma ([@b0665]) and c9orf72 genes ([@b0245]), and were comparable to findings in sporadic ALS patients. Significant correlations between cortical hyperexcitability and peripheral neurodegeneration have also been established ([@b0640], [@b0245]). Interestingly, asymptomatic mutation carriers exhibited normal cortical function ([@b0635], [@b0245]), with features of hyperexcitability preceding the clinical development of familial ALS by months ([@b0635]).

Findings in sporadic and familial ALS cohorts have supported the notion that ALS is mediated by a multistep process ([@b0010]), with cortical hyperexcitability (and specifically dysfunction of cortical interneuronal circuits) being potentially an important step in ALS pathogenesis. This view is supported by studies in the TDP-43^A315T^ mouse model whereby hyperactivity of excitatory cortical interneurons underlies the development of hyperexcitability in cortical output tracts ([@b0695]). From a therapeutic perspective, focal ablation of excitatory interneuronal circuits may lead to normalization of excitability and potentially neuroprotection, a hypothesis that needs to be further assessed.

The notion that cortical dysfunction is a compensatory mechanism in response to motor neuron degeneration in ALS has been suggested ([@b0690]). Given that ALS mimicking disorders, such as Kennedys disease, acquired neuromyotonia, demyelinating sensorimotor radiculopolyneuropathy and multifocal motor neuropathy with conduction block, exhibit normal cortical function, despite a comparable peripheral disease burden ([@b0635], [@b0640], [@b0390]), potentially argued against such a notion.

There has been a paucity of studies assessing the SICF changes in sporadic ALS. Recently, a significant increase in SICF was reported in ALS, and this increase was accompanied by reduction in SICI ([@b0575]). The index of excitation, a novel neurophysiological biomarker of cortical excitability, was increased in ALS patients suggesting that overactivity of facilitatory circuits contribute to hyperexcitability. There was a significant correlation between this index of excitation and functional disability, underscoring the pathogenic importance of facilitatory circuit overactivity in ALS, thereby providing a potential therapeutic target.

Reduction or absence of LICI has been previously reported in sporadic ALS using the constant stimulus TMS technique ([@b0690], [@b0685]). The reduction in LICI was accompanied by reductions in SICI, and both correlated with disease severity and the degree of upper motor neuron dysfunction. Degeneration of GABAergic cortical neurons was postulated to underlie these abnormalities of cortical inhibition and to form the pathogenic basis of ALS.

2. Single-pulse threshold tracking TMS {#s0035}
======================================

2.1. Physiology of motor thresholds (MT) {#s0040}
----------------------------------------

Motor thresholds reflect the excitability of corticomotoneurons located in the motor cortex ([@b0470]). Originally, the MT was defined as the minimum stimulus intensity required to elicit a small motor evoked potential (usually peak-peak ≥ 50 μV) in 50% of trials utilizing the constant stimulus technique ([@b0470]). Threshold-tracking TMS defines MT as the stimulus intensity required to elicit and maintain a target motor evoked potential (MEP) response of 200 μV ([@b0025], [@b0225], [@b0600], [@b0275]). From a physiological perspective, motor thresholds reflect the density of corticomotoneuronal (CM) projections onto the spinal or bulbar motor neuron, with MTs being lowest for intrinsic hand muscles due to a higher density of CM projections ([@b0075], [@b0370], [@b0120]). In addition, MTs are influenced by the TMS pulse width and waveform, such that longer and monophasic TMS pulse-widths, directed in a posterior-anterior direction, lead to lower MTs. These findings suggest that neuronal populations contributing to MT predominantly reside in the anterior bank of the central sulcus ([@b0090]).

In addition to density of corticomotoneuronal projections, MTs are also modulated by a variety of pharmacological agents ([@b0715]). Specifically, voltage-gated Na^+^ channel blocking agents, such as tegretol, dilantin or lamotrigine, increase MT, ([@b0375], [@b0060], [@b0510], [@b0365]), suggesting the importance of Na^+^ channel-mediated axonal excitability in determining motor thresholds. MT is decreased by enhancing glutamatergic neurotransmission via AMPA receptors ([@b0165]), but the effects on MT of other neurotransmitter systems and of voltage gated Ca^2+^ channels have been inconsistent ([@b0715]). This underscores the complex physiology of motor thresholds.

2.2. Pathophysiological implications of motor thresholds in ALS {#s0045}
---------------------------------------------------------------

Although some studies have reported normal MTs ([@b0085], [@b0335], [@b0415], [@b0690], [@b0600], [@b0635], [@b0385]), a reduction in threshold may occur in ALS patients, being more prominent over the dominant motor cortex and the cortex that is contralateral to site of disease onset ([@b0385]). Increased MTs or inexcitable motor cortices have also been documented in ALS ([@b0205], [@b0040], [@b0545], [@b0420], [@b0550], [@b0565], [@b0140], [@b0020]). The variable findings may relate to the clinical and pathological heterogeneity of ALS, the stage at which the disease is assessed and rate of disease progression. Reduction in MTs have been documented in the early stages of ALS, and this reduction in MTs was associated with clinical features of profuse fasciculations, preserved muscle bulk and hyper-reflexia ([@b0415], [@b0210]). These findings could also reflect the presence of spinal motor neuron hyperexcitability, with the reduction in cortical thresholds reflecting a smaller corticospinal volley required to activate the lower motor neuronal pool. With disease progression, a progressive increase in MTs ensues, eventually leading to motor cortex inexcitability ([@b0415]). However, a decrease in MT was shown to be an independent predictor of cognitive dysfunction in ALS ([@b0005]).

2.3. Physiology of MEP amplitude {#s0050}
--------------------------------

The MEP amplitude is measured from MEPs evoked by suprathreshold TMS stimuli and reflect a summation of descending corticospinal volleys consisting of D (direct) and I-waves ([@b0015], [@b0175], [@b0470]). The MEP amplitude increases with higher TMS stimulus intensity and the resulting stimulus-response curve follows a sigmoid function ([@b0150]). As with MT, the MEP amplitude reflects the density of corticomotoneuronal projections onto motor neurons, provided that spinal mechanisms are controlled ([@b0700]). Typically, the MEP is expressed as a percentage of the maximum compound muscle action potential (CMAP) amplitude in order to control for peripheral nerve conduction, thereby providing insight into the percentage of the motor neurone pool activated in the MEP ([@b0470]). When compared to MT, the MEP amplitude may give insight into neurons that are less excitable or further away from the centre of the TMS induced electrical field ([@b0105]).

Large inter-subject variability has been reported for MEP amplitudes, an observation attributed to fluctuations in neuronal excitability at the cortical and spinal cord levels ([@b0470]). The MEP amplitudes correlate with the power and phase of EMG and EEG in a frequency band around 18 Hz in wakeful states and up-phase of slow oscillations in non-REM sleep ([@b0045], [@b0215], [@b0320]). In addition, the MEP amplitude is increased by muscle contraction, underscoring its role as an important biomarker of state dependency of cortical excitability.

As with motor thresholds, a variety of CNS neurotransmitter systems modulate MEP amplitudes ([@b0715]). Specifically, GABAergic agonists reduce MEP amplitudes, while glutamatergic and noradrenergic agonists increase MEP amplitudes ([@b0315], [@b0060], [@b0435], [@b0440], [@b0165], [@b0300]). In contrast, modulators of voltage-gated Na^+^ channels did not exert any significant effects on MEP amplitude, indicating that the physiological processes mediating MEP amplitudes are independent to those underlying MT.

2.4. MEP amplitude and pathophysiological implications in ALS {#s0055}
-------------------------------------------------------------

Greater MEP amplitudes have been reported in sporadic and familial forms of ALS, being most prominent in early stages of the disease ([@b0600], [@b0610], [@b0635], [@b0400], [@b0245], [@b0390], [@b0405], [@b0230]). The increase in MEP amplitude appears to be more prominent over the dominant motor cortex which is contralateral to the side of disease onset ([@b0385]). This increase in MEP amplitude correlates with surrogate biomarkers of motor neuron degeneration ([@b0600], [@b0640]). While cortical hyperexcitability could account for the bigger MEP amplitudes, the state of the spinal cord circuitry may also be an important modulator of MEP amplitudes in ALS patients. A descending TMS-induced volley would elicit a greater discharge in the setting of spinal motor neuron hyperexcitability. Consequently, the higher MEP amplitudes and lower cortical thresholds evident in ALS patients could also be mediated by spinal motor neuronal hyperexcitability. Separately, MEP amplitudes were normal in non-ALS mimic disorders, despite a comparable degree of lower motor neuron dysfunction, thereby arguing against the notion that cortical plasticity was responsible for increased MEP amplitudes in ALS ([@b0635], [@b0640], [@b0385]).

2.5. Physiology of the cortical silent period (CSP) duration {#s0060}
------------------------------------------------------------

The CSP refers to a period of electrical inactivity in the background voluntary EMG signal that occurs immediately after a TMS stimulus delivered over the contralateral motor cortex ([@b0080]). The CSP duration is measured from onset of the facilitated MEP to resumption of voluntary EMG activity and may vary from 100 to 300 ms, being dependent on the strength of the TMS stimulus ([@b0080], [@b0310], [@b0540], [@b0700], [@b0470]). CSP duration appears to be determined by a combination of spinal inhibitory mechanisms and long latency inhibitory cortical processes. Specifically, the early part of the CSP duration (∼the first 50 ms) appears to be spinal in origin, mediated by activation of Renshaw cells and Ia inhibitory interneurons, as well as refractoriness of spinal motor neurons ([@b0470]). The long duration of the CSP is probably due to activation of cortical inhibitory neurons acting predominantly via GABA~B~ receptors ([@b0080], [@b0310], [@b0505], [@b0115], [@b0655]), although a role for GABA~A~ receptor function has also been reported at lower stimulus intensities ([@b0655], [@b0525]). Separately, the CSP duration is longer in the upper limbs, suggesting an importance of the density of corticomotoneuronal projections onto motor neurons in regulating CSP ([@b0105]).

2.6. Pathophysiological implication of reduced CSP duration in ALS {#s0065}
------------------------------------------------------------------

A reduction of CSP duration has been documented in sporadic and familial ALS phenotypes, and is most prominent in the early stages of the disease ([@b0445], [@b0145], [@b0500], [@b0690], [@b0410], [@b0600], [@b0675], [@b0635], [@b0640], [@b0245], [@b0260], [@b0270], [@b0230]). Reduction in CSP duration has also been established in atypical ALS phenotypes, such as the flail arm and leg variants of ALS ([@b0610], [@b0395]). This reduction of CSP duration most likely represents degeneration and dysfunction of GABAergic inhibitory neurotransmission. As with other TMS parameters, the reduction of CSP duration is a specific feature of ALS in the context of neuromuscular diseases ([@b0635], [@b0640], [@b0595], [@b0390]).

2.7. Threshold tracking TMS, site of disease onset and patterns of disease spread {#s0070}
---------------------------------------------------------------------------------

The site of ALS onset remains an important and unresolved issue in the understanding of ALS pathogenesis. Resolution of this quandary has implications for identifying appropriate therapeutic targets and treatment strategies ([@b0250]). Jean Martin Charcot first published on the importance of UMN dysfunction in ALS pathogenesis ([@b0100]), a theory that was crystalized in the *dying forward hypothesis* some 100 years later ([@b0200]). Eisen and colleagues proposed that motor neuron degeneration was mediated by an anterograde excitotoxic mechanism ([@b0200]). This hypothesis was supported by clinical observations of dissociated wasting of intrinsic hand muscles (split-hand and split-hand plus phenomenon) in ALS ([@b0660], [@b0355], [@b0380], [@b0400]). Importantly, cortical hyperexcitability appears to underlie the development of both the split-hand and split-hand plus phenomenon ([@b0030], [@b0400]), underscoring the primacy of UMN dysfunction in ALS pathogenesis.

Cortical hyperexcitability has been identified as an early feature of sporadic ALS, correlating with biomarkers of motor neuron degeneration ([@b0600]). Furthermore, cortical hyperexcitability was shown to precede the development of detectible LMN dysfunction in sporadic ALS and the clinical onset of familial ALS phenotypes ([@b0635], [@b0405]). While there remains a possibility that upper and lower motor neurons degenerate independently or that ALS begins at a peripheral level (muscle or neuromuscular junction as suggested by the dying-back hypothesis), threshold tracking TMS provides indirect support for the primacy of corticomotoneurons in ALS pathogenesis, namely the dying forward mechanism.

Separately, upper motor neuron dysfunction has been implicated in the patterns of disease spread in ALS. This notion is supported by clinical observations that limb dominance is a significant factor in underlying the site of disease onset in ALS ([@b0560], [@b0155]). In addition, cortical hyperexcitability is more prominent over the motor cortex contralateral to the side of disease onset ([@b0385]). Separately, a comparable degree of cortical hyperexcitability was evident in patients exhibiting contiguous and non-contiguous patterns of spread, suggesting the importance of cortical processes in mediating disease evolution in ALS.

The precise mechanisms by which cortical hyperexcitability contributes to ALS spread remain to be fully elucidated, although it's likely to be complex and multifactorial ([@b0250]). A number of previously implicated molecular processes, including oxidative stress, paracrine signalling, mitochondrial dysfunction, neuroimmunotoxicity, abnormalities of protein folding and transmembrane signalling, along with non-neuronal cell dysfunction and prion-like spread could be operative at the central nervous system level ([@b0460], [@b0195]). ALS appears to be a multi-step disease requiring 6 critical events for development ([@b0010]). Genetic mutations, epigenetic and environmental factors as well as dysfunction of molecular processes, appear to be potential steps ([@b0010], [@b0125]). Cortical hyperexcitability may be a critical final step in the pathogenic process for ALS. Contiguous and non-contiguous patterns of disease spread could be explained by development of hyperexcitability in specific corticomotoneurons and the motor cortex, with disease spread evolving along the neocortex and under direct control of corticofugal projections, namely the neurons that project outward from the primary motor cortex ([@b0190]). Future studies should assess the evolution of cortical excitability changes in sporadic and familial ALS cohorts, relating these cortical changes to clinical and anatomical patterns of disease spread by combining the threshold tracking TMS with TMS-EEG, quantitative and functional MRI techniques.

2.8. Diagnostic utility of threshold tracking TMS in ALS {#s0075}
--------------------------------------------------------

The diagnosis of ALS relies on identifying concomitant upper and lower motor neuron signs, with evidence of rapid disease progression ([@b0325]). Given the absence of a diagnostic test, clinically based criteria have been developed in order to facilitate an earlier diagnosis of ALS ([@b0065], [@b0070]). The clinically based criteria have exhibited poor sensitivity, particularly in early stages of the disease ([@b0555], [@b0130], [@b0235], [@b0255]). In order to increase the diagnostic yield, a neurophysiologically based Awaji-Shima criteria were proposed in 2006 ([@b0135]). While the Awaji criteria have a greater sensitivity ([@b0130], [@b0235], [@b0255]), the major limitation pertained to the reliance on clinical assessment for identifying UMN dysfunction. In part, this limitation relates to difficulties in identifying UMN signs in ALS patients, especially in the setting of weak muscle and wasting ([@b0295], [@b0530]).

The threshold tracking TMS technique has proven to be a robust and objective biomarker of UMN dysfunction in ALS ([@b0595], [@b0265], [@b0390]). The presence of cortical dysfunction, as heralded by reduction of SICI or motor cortex inexcitability, reliably differentiated ALS from neuromuscular mimicking disorders, hastening the diagnosis of ALS by ∼8 months when compared to clinical criteria ([@b0595]). Importantly, identification of cortical dysfunction enhances the diagnostic utility of the Awaji criteria by 34%, irrespective of disease stage or site of onset ([@b0390]). Furthermore, sub-clinical UMN dysfunction has been identified in atypical ALS phenotypes by utilising the threshold tracking TMS technique ([@b0610], [@b0395]), and thereby further aiding the diagnosis of ALS.

Combining threshold tracking TMS with quantitative neuroimaging (Magnetic Resonance imaging) techniques has increased the sensitivity of detecting UMN dysfunction in ALS ([@b0270]). Notably, the presence of cortical thinning in the precentral gyrus (motor cortex) along with features of cortical hyperexcitability, identified UMN dysfunction in 88% of ALS patients ([@b0270]). Future ALS diagnostic criteria may consider incorporating functional (TMS) and structural (MRI) biomarkers of UMN dysfunction as a means of enhancing the diagnosis. Such an approach may result in an earlier recruitment of patients into clinical trials, at a stage when neuroprotective therapies may be more efficacious ([@b0195]).

3. Conclusion {#s0080}
=============

In conclusion, the threshold tracking TMS technique has provided invaluable pathophysiological insights in sporadic and familial ALS. Cortical hyperexcitability has been identified as an important feature in ALS, preceding the onset of neurodegeneration and correlating with biomarkers of motor neuronal loss. In addition, the site of disease onset and patterns of disease spread appear to be mediated by corticomotoneuronal hyperexcitability. Separately, the threshold tracking TMS technique has yielded a robust and objective biomarker of upper motor neuron dysfunction in ALS, leading to earlier diagnosis. Future studies incorporating threshold tracking TMS along with other physiological techniques, such as TMS-EEG, neuroimaging as well molecular and genetic techniques may shed further insights into the mechanisms triggering cortical dysfunction and potentially identifying much needed therapeutic targets.
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